慢性眼病生物科技公司SpyGlass Pharma(SGP.US)IPO定价15-17美元/股拟募资1.5亿美元

智通财经01-30

智通财经APP获悉，专注慢性眼病治疗植入物研发、处于三期临床试验阶段的生物科技企业SpyGlass Pharma(SGP.US)于周四公布其首次公开发行(IPO)的发行条款。这家总部位于美国加利福尼亚州阿利索维耶霍市的企业，计划以每股15-17美元的价格发行940万股股票，募资1.5亿美元。按拟议发行价区间中值计算，SpyGlass Pharma的完全摊薄后市值将达5.49亿美元。SpyGlass...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2607009988?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-01-30 14:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2607009988","market":"us","top_or_hot":-1,"title":"慢性眼病生物科技公司SpyGlass Pharma(SGP.US)IPO定价15-17美元/股 拟募资1.5亿美元","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，专注慢性眼病治疗植入物研发、处于三期临床试验阶段的生物科技企业SpyGlass Pharma(SGP.US)于周四公布其首次公开发行(IPO)的发行条款。这家总部位于美国加利福尼亚州阿利索维耶霍市的企业，计划以每股15-17美元的价格发行940万股股票，募资1.5亿美元。按拟议发行价区间中值计算，SpyGlass Pharma的完全摊薄后市值将达5.49亿美元。SpyGlass...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1399684.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>慢性眼病生物科技公司SpyGlass Pharma(SGP.US)IPO定价15-17美元/股 拟募资1.5亿美元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n慢性眼病生物科技公司SpyGlass Pharma(SGP.US)IPO定价15-17美元/股 拟募资1.5亿美元\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-30 14:55 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1399684.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，专注慢性眼病治疗植入物研发、处于三期临床试验阶段的生物科技企业SpyGlass Pharma(SGP.US)于周四公布其首次公开发行(IPO)的发行条款。这家总部位于美国加利福尼亚州阿利索维耶霍市的企业，计划以每股15-17美元的价格发行940万股股票，募资1.5亿美元。按拟议发行价区间中值计算，SpyGlass Pharma的完全摊薄后市值将达5.49亿美元。SpyGlass...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1399684.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LABU","symbol_name":"三倍做多标普生物-Direxion","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1399684.html","article_id":"2607009988","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2607009988","pubTimestamp":1769756130,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，专注慢性眼病治疗植入物研发、处于三期临床试验阶段的生物科技企业SpyGlass Pharma于周四公布其首次公开发行的发行条款。这家总部位于美国加利福尼亚州阿利索维耶霍市的企业，计划以每股15-17美元的价格发行940万股股票，募资1.5亿美元。按拟议发行价区间中值计算，SpyGlass Pharma的完全摊薄后市值将达5.49亿美元。SpyGlass Pharma成立于2019年，计划在纳斯达克挂牌上市，股票代码为“SGP”。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159837":"生物科技","LABU":"三倍做多标普生物-Direxion","BK4588":"碎股","BK4585":"ETF&股票定投概念"},"translate_title":"Chronic eye disease biotechnology company SpyGlass Pharma (SGP.US) IPO priced at US $15-17 per share and plans to raise US $150 million","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159837":1.5,"LABU":1.5},"content_text":"智通财经APP获悉，专注慢性眼病治疗植入物研发、处于三期临床试验阶段的生物科技企业SpyGlass Pharma(SGP.US)于周四公布其首次公开发行(IPO)的发行条款。这家总部位于美国加利福尼亚州阿利索维耶霍市的企业，计划以每股15-17美元的价格发行940万股股票，募资1.5亿美元。按拟议发行价区间中值计算，SpyGlass Pharma的完全摊薄后市值将达5.49亿美元。SpyGlass Pharma是一家临床后期生物制药企业，聚焦慢性眼病领域，专注于通过开发持久的给药解决方案来治疗慢性眼病，以实现长期疾病控制和视力保护。公司核心在研产品为比马前列素药垫人工晶状体系统(BIM-IOL系统)，该系统将自主研发的新型药垫与人工晶状体相结合，可在常规白内障手术中完成植入，用于降低开角型青光眼(OAG)或高眼压症(OHT)患者的升高眼压。此外，公司还在研发一款非人工晶状体载体的比马前列素环形缓释植入物，该产品可通过独立手术完成植入，既可为已植入BIM-IOL系统的患者提供二次治疗方案，也能为既往接受过白内障手术的开角型青光眼或高眼压症患者提供延续性治疗。SpyGlass Pharma成立于2019年，计划在纳斯达克挂牌上市，股票代码为“SGP”。Jefferies、Leerink Partners、花旗及Stifel为此次IPO的联席簿记管理人。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2607009988","isCrawlerRequest":true}

慢性眼病生物科技公司SpyGlass Pharma(SGP.US)IPO定价15-17美元/股 拟募资1.5亿美元

精彩评论

慢性眼病生物科技公司SpyGlass Pharma(SGP.US)IPO定价15-17美元/股拟募资1.5亿美元